3 terminated. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow COVID 19: new trials by email Literature Review of COVID 19 trials Research Report on COVID 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Linagliptin 5 MG - COVID 19, Coronavirus | Phase 3 | Terminated | Rabin Medical Center | 64 | 2020-10-01 | 2021-06-02 |
| Inhaled Ciclesonide for Outpatients With COVID19 Normal Saline intranasal and placebo inhaler, Ciclesonide, Ciclesonide nasal - COVID 19 | Phase 2 / Phase 3 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 215 | 2020-09-15 | 2022-06-10 |
| Trial of Hydroxychloroquine In Covid-19 Kinetics Hydroxychloroquine, Placebo - Covid 19, Corona Virus Infection | Phase 2 / Phase 3 | Terminated | University of South Alabama | 3 | 2020-04-17 | 2022-01-03 |
COVID-19 (3) · Coronavirus Infections (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Respiratory Tract Diseases (1)
Coronaviridae Infections (3) · Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · RNA Virus Infections (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Respiratory Tract Diseases (2) · Coronavirus Infections (1) · Nutritional and Metabolic Diseases (1)
Hydroxychloroquine (1) · Linagliptin (1) · ciclesonide (1)
McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Rabin Medical Center (1) · University of South Alabama (1)
Canada (1) · Israel (1) · United States (1)